Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93,104,451
-
Number of holders
-
208
-
Total 13F shares, excl. options
-
79,271,409
-
Shares change
-
+3,755,463
-
Total reported value, excl. options
-
$2,560,639,030
-
Value change
-
+$122,124,573
-
Put/Call ratio
-
55%
-
Number of buys
-
101
-
Number of sells
-
-78
-
Price
-
$32.29
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q3 2021
233 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q3 2021.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 208 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79,271,409 shares
of 93,104,451 outstanding shares and own 85.14% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13,561,305 shares), VANGUARD GROUP INC (9,033,197 shares), EARNEST PARTNERS LLC (6,251,811 shares), STATE STREET CORP (4,294,833 shares), WELLINGTON MANAGEMENT GROUP LLP (3,231,212 shares), PFM Health Sciences, LP (2,872,918 shares), Camber Capital Management LP (2,750,000 shares), DIMENSIONAL FUND ADVISORS LP (2,686,376 shares), BANK OF AMERICA CORP /DE/ (2,587,062 shares), and GLENVIEW CAPITAL MANAGEMENT, LLC (2,235,168 shares).
This table shows the top 208 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.